Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma
OBJECTIVES: I. Evaluate the clinical activity of troglitazone in patients with malignant
liposarcoma. II. Evaluate the tolerance and safety of troglitazone in this patient
OUTLINE: This is an open label trial. All patients are given a single dose of oral
troglitazone daily. Patients continue to receive troglitazone as long as their disease
responds to treatment or remains stable.
PROJECTED ACCRUAL: Initially, 14 patients of each of the 5 subtypes of liposarcoma will be
accrued. If 1 or more patients show evidence of biological response, an additional 16
patients of each subtype will be accrued for a total of 30 per subtype.
Primary Purpose: Treatment
George D. Demetri, MD
Dana-Farber Cancer Institute
United States: Federal Government
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Brigham and Women's Hospital||Boston, Massachusetts 02115|